Related Experiment Video
Updated: Jun 3, 2025
Oropharyngeal Administration of Bleomycin in the Murine Model of Pulmonary Fibrosis
Published on: May 9, 2025
The Cyclin-Dependent Kinase 8 Inhibitor E966-0530-45418 Attenuates Pulmonary Fibrosis In Vitro and In Vivo
Ching-Hsuan Chou1, Wei-Jan Huang2,3, Kai-Cheng Hsu4,5
1School of Pharmacy, College of Medicine, National Taiwan University, Taipei, Taiwan.
Abstract:
Pulmonary fibrosis (PF) is a high-mortality lung disease with limited treatment options, highlighting the need for new therapies. Cyclin-dependent kinase 8 (CDK8) is a promising target due to its role in regulating transcription via the TGF-β/Smad pathway, though CDK8 inhibitors have not been thoroughly studied for PF. This study aims to evaluate the potential of E966-0530-45418, a novel CDK8 inhibitor, in mitigating PF progression and explores its underlying mechanisms. We discovered that CDK8 is upregulated in lung tissues from idiopathic pulmonary fibrosis patients and in a bleomycin-induced PF mouse model. Our study further revealed that E966-0530-45418 inhibits PF progression by attenuating the activity of the transcription factor Smad3, which is involved in TGF-β1/Smad signaling, along with RNA polymerase II to downregulate fibrosis-associated protein expression in alveolar epithelia and lung fibroblasts and consequently mitigate myofibroblast differentiation and collagen deposition. E966-0530-45418 also blocks STAT3 signaling to obstruct M2 macrophage polarization, further suppressing PF progression. Moreover, E966-0530-45418 administration ameliorated lung function deterioration and lung parenchymal destruction in the bleomycin-induced PF mouse model. These findings indicate that E966-0530-45418 holds promise as a pioneering CDK8 inhibitor for treating PF.
Insights
A novel drug, E966-0530-45418, shows promise in treating pulmonary fibrosis (PF) by inhibiting Cyclin-dependent kinase 8 (CDK8). This new therapy targets key fibrotic pathways, offering hope for patients with this severe lung disease.
Area of Science:
- Pulmonary Medicine
- Molecular Biology
- Pharmacology
Background:
- Pulmonary fibrosis (PF) is a fatal lung disease with limited therapeutic strategies.
- Cyclin-dependent kinase 8 (CDK8) is implicated in fibrotic processes via the TGF-β/Smad pathway.
- CDK8 inhibitors are underexplored for PF treatment.
Purpose of the Study:
- To investigate the therapeutic potential of the novel CDK8 inhibitor E966-0530-45418 in pulmonary fibrosis.
- To elucidate the underlying molecular mechanisms of E966-0530-45418 in mitigating PF.
Main Methods:
- Assessed CDK8 expression in human IPF lung tissues and a bleomycin-induced PF mouse model.
- Evaluated E966-0530-45418's effects on TGF-β1/Smad3 signaling, RNA polymerase II activity, and fibrosis markers.
- Examined the impact of E966-0530-45418 on STAT3 signaling, M2 macrophage polarization, and lung function in the PF mouse model.
Main Results:
- CDK8 was upregulated in idiopathic pulmonary fibrosis (IPF) patient lungs and a mouse model.
- E966-0530-45418 inhibited Smad3 and RNA polymerase II activity, reducing fibrosis-associated proteins, myofibroblast differentiation, and collagen deposition.
- The inhibitor also blocked STAT3 signaling, preventing M2 macrophage polarization and ameliorating lung function and damage in mice.
Conclusions:
- E966-0530-45418 effectively inhibits PF progression by targeting CDK8 and downstream fibrotic pathways.
- The drug reduces myofibroblast activation and modulates immune responses involved in fibrosis.
- E966-0530-45418 demonstrates significant therapeutic promise as a novel treatment for pulmonary fibrosis.
More Related Videos
07:38A Multimodal Imaging Approach Based on Micro-CT and Fluorescence Molecular Tomography for Longitudinal Assessment of Bleomycin-Induced Lung Fibrosis in Mice
Published on: April 13, 2018
02:46A Mouse Model of Pulmonary Fibrosis Induced by Nasal Bleomycin Nebulization
Published on: January 20, 2023
